Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Terminated Phase 4 Interventional Results available

Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles

ClinicalTrials.gov ID: NCT02015663

Public ClinicalTrials.gov record NCT02015663. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 9:54 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A 24-week, Open-label, Parallel-group, Interventional Phase IV Study Comparing Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles for the Treatment of Pulmonary Pseudomonas Aeruginosa in Patients With Cystic Fibrosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To provide efficacy and safety data comparing two dosing schedules of Tobramycin Inhalation Powder (TIP) for the treatment of pulmonary Pseudomonas aeruginosa in patients with cystic fibrosis.

Study identification

NCT ID
NCT02015663
Recruitment status
Terminated
Study type
Interventional
Phase
Phase 4
Lead sponsor
Novartis Pharmaceuticals
Industry
Enrollment
32 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
6 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 2014 (Type not available)
Primary completion
Dec 2014 (Actual)
Completion
Dec 2014 (Actual)
Last update posted
Mar 29, 2017

2014

United States locations

U.S. sites
21
U.S. states
14
U.S. cities
21
Facility City State ZIP Site status
Novartis Investigative Site Mobile Alabama 36608-1128 —
Novartis Investigative Site Los Angeles California 90027 —
Novartis Investigative Site Sacramento California 95819 —
Novartis Investigative Site Ventura California 93003 —
Novartis Investigative Site Altamonte Springs Florida 32701 —
Novartis Investigative Site Jacksonville Florida 32207 —
Novartis Investigative Site Miami Florida 33136 —
Novartis Investigative Site Orlando Florida 32806 —
Novartis Investigative Site Pensacola Florida 32504 —
Novartis Investigative Site Glenview Illinois 60025 —
Novartis Investigative Site Indianapolis Indiana 46202 —
Novartis Investigative Site Iowa City Iowa 52242 —
Novartis Investigative Site St Louis Missouri 63104 —
Novartis Investigative Site New Hyde Park New York 11040 —
Novartis Investigative Site New York New York 10595 —
Novartis Investigative Site Akron Ohio 44308 —
Novartis Investigative Site Oklahoma City Oklahoma 73112 —
Novartis Investigative Site Portland Oregon 92772 —
Novartis Investigative Site Hershey Pennsylvania 17033-8050 —
Novartis Investigative Site Austin Texas 78723 —
Novartis Investigative Site Salt Lake City Utah 84132 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02015663, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 29, 2017 · Synced Oct 21, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02015663 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →